Close

Form 4 Oncocyte Corp For: Dec 01 Filed by: ANDREWS RONALD ASBURY

December 9, 2022 8:24 PM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
ANDREWS RONALD ASBURY

(Last) (First) (Middle)
15 CUSHING

(Street)
IRVINE CA 92618

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oncocyte Corp [ OCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Former CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/01/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, no par value 12/01/2022   M   250,000 A $ 0 583,212 D  
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock $ 2.1 12/01/2022   D     20,000   (1)   (1) Common Stock 20,000 $ 0 0 D  
Option to Purchase Common Stock $ 2.4 12/01/2022   D     45,000   (1)   (1) Common Stock 45,000 $ 0 0 D  
Option to Purchase Common Stock $ 2.51 12/01/2022   D     950,000   (1)   (1) Common Stock 950,000 $ 0 0 D  
Option to Purchase Common Stock $ 1.68 12/01/2022   D     50,000   (1)   (1) Common Stock 50,000 $ 0 0 D  
Option to Purchase Common Stock $ 5.34 12/01/2022   D     500,000   (1)   (1) Common Stock 500,000 $ 0 0 D  
Option to Purchase Common Stock $ 1.15 12/01/2022   D     300,000   (1)   (1) Common Stock 300,000 $ 0 0 D  
Option to Purchase Common Stock $ 1.15 12/01/2022   D     93,750   (1)   (1) Common Stock 93,750 $ 0 281,250 D  
Restricted Stock Units $ 0 12/01/2022   D     35,000   (2)   (2) Common Stock 35,000 $ 0 0 D  
Restricted Stock Units $ 0 12/01/2022   D     250,000   (2)   (2) Common Stock 250,000 $ 0 250,000 D  
Restricted Stock Units $ 0 12/01/2022   M     250,000   (2)   (2) Common Stock 250,000 $ 0 0 D  
Option to Purchase Common Stock $ 0.4644 12/07/2022   A   50,000     (3) 12/07/2032 Common Stock 50,000 $ 0 50,000 D  
Explanation of Responses:
1. The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022.
2. The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022.
3. Options vest (and thereby become exercisable) as follows: (i) one-third on December 31, 2022, (ii) one-third on January 31, 2023, and (iii) one-third on February 28, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date.
/s/ Ronald Andrews 12/09/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings